drugset
drugset / Trial / NCT04563377

Safety and Immunogenicity of Candidate HIV Vaccines Given Sequentially

NCT04563377 ↗

Phase 1/2 Completed 10 enrolled University of Oxford
NaSingle-groupOpen-labelOther

Summary

The primary object of the study is to assess the safety profile of candidate vaccines ChAdOx1.HTI and MVA.HTI administered sequentially in healthy HIV-1/2 negative adult volunteers. In addition, the study will assess the immune responses generated of the candidate vaccines ChAdOx1.HTI and MVA.HTI administered sequentially in healthy HIV-1/2 negative adult volunteers. 10 healthy, HIV-negative adult volunteers will receive one vaccination of CHAdOx1.HTI followed by a one vaccination of MVA.HTI 8 weeks later.

Timeline

Start
2021-11-01
Primary completion
2022-08-16
Completion
2022-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject ChAdOx1.HTI Vaccine 5e+10 unknown —
Subject MVA.HTI Vaccine 2e+08 unknown —

Indications

No indication recorded.